Objective responses, good safety and evidence of stimulation of the immune system were observed with GM102 administered as a single agent in the dose-finding escalation part of the study
AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy
This designation has been awarded for the treatment of AMHR2-expressing ovarian cancers, exclusive of AMHR2-expressing fallopian tube cancers and primary peritoneal cancers
First trial of mAb targeting anti-Müllerian human receptor II tested in oncology patients
Initial results expected in 2017
BioDiscovery 4, a fund managed by Edmond de Rothschild Investment Partners, led the round; the funds raised will finance clinical trials for GM102, a therapeutic antibody targeting gynecological cancers
GamaMabs Pharma will present new results from its collaboration with the Institut Curie at TAT meeting (Paris, March 2-4 2015) with a poster describing 3C23K antibody efficacy in combination with chemotherapy in PDX models.
Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer.